News

At the 2023 ASRS meeting in Seattle, Washington, Diana Do, MD joined our team to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema.

This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.

6-Month results underscore treatment safety with suprachoroidally injected ABBV-RGX-314 for nAMD

In a presentation at the American Society of Retina Specialists 41st Annual Meeting in Seattle, Diana Do, MD, said the PHOTON study demonstrated the impact aflibercept 8 mg could have in reducing the treatment burden for patients diagnosed with DME.

According to the company, a pair of presentations at the American Society of Retina Specialists annual meeting in Seattle highlight CLS-AX as a promising wet AMD treatment with a new mechanism of action and the potential for longer duration of effect than current therapies.

Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

Carl Danzig, MD, spoke with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS annual meeting.

At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, spoke with our team about his research and how changes are making new training possible. He shared how research and new techniques are expanding the options for deep learning in ophthalmology.

Jennifer I. Lim, MD, FARVO, FASRS shares insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis."

Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.

With the potential to impact millions of patients, a study finds that biomimetic materials pulsed with low-energy blue light can reshape damaged corneas, including thickening the tissue.

Detrimental effects of IVB may not be recognized at an early age, which underscores the importance of following these children over time.

Hungarian investigators reported the beneficial use of optical coherence tomography (OCT) for detecting macular pathologies in patients with scleritis.

Researchers found that using automated methods to determine the VA showed “robust performance in predicting visual impairment”

The next Ophthalmic World Leaders Leadership Summit will take place in Austin, TX, on September 21 and 22, 2023.

The College of Health Care Professions will offer a blended 36-week certificate program to meet the growing demand for ophthalmology assistants across the Dallas-Forth Worth region.

The intraocular injection of AXT107 microparticulate suspension will be explored in the DISCOVER study.

The company announced it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.

OPT-302 is the company’s novel recombinant “trap” fusion protein targeting inhibition of vascular endothelial growth factors C and D, two ligand mediators of angiogenesis and vascular leakage involved in retinal vascular diseases.

HLX04-O has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

Ophthalmologist offers pearls for use of technology in daily work.

According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.

According to the companies, this partnership will leverage RetinAI's innovative digital health technologies and RCA's network of clinics to analyze real-world health clinical and imaging data.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference will mean for clinicians and addresses the anticipated increased patient volume.

The company also provided an update on tarcocimab development program for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

With lawsuits looming over the issue, the FDA has updated the label on Horizon Pharmaceutical’s drug for thyroid eye disease to include risks associated with hearing loss.